Ernexa selected as company for JETRO Japan entry acceleration program

Ernexa Therapeutics (ERNA) announced it has been selected as one of only ten companies worldwide to participate in the Japan Entry Acceleration Program, JEAP, an initiative launched by the Japan External Trade Organization, JETRO. As a selected participant, Ernexa will receive expert-led mentoring and market-entry guidance focused on Japan’s regulatory, clinical and commercial landscape. The program also provides direct engagement opportunities with leading Japanese research and development organizations, including CDMOs and CROs, to explore potential collaborations across development, manufacturing and clinical execution.